E Fund Management Co. Ltd. purchased a new position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,103 shares of the company’s stock, valued at approximately $38,000.
A number of other large investors have also bought and sold shares of ITOS. Janus Henderson Group PLC raised its position in iTeos Therapeutics by 98.8% in the fourth quarter. Janus Henderson Group PLC now owns 1,988,130 shares of the company’s stock worth $64,662,000 after purchasing an additional 988,298 shares in the last quarter. Cowen AND Company LLC acquired a new stake in shares of iTeos Therapeutics during the first quarter worth approximately $20,106,000. BlackRock Inc. increased its holdings in shares of iTeos Therapeutics by 44.0% during the first quarter. BlackRock Inc. now owns 1,533,322 shares of the company’s stock worth $52,409,000 after buying an additional 468,576 shares in the last quarter. Alliancebernstein L.P. increased its holdings in shares of iTeos Therapeutics by 43.0% during the fourth quarter. Alliancebernstein L.P. now owns 1,098,100 shares of the company’s stock worth $37,138,000 after buying an additional 330,016 shares in the last quarter. Finally, Asymmetry Capital Management L.P. increased its holdings in shares of iTeos Therapeutics by 139.6% during the fourth quarter. Asymmetry Capital Management L.P. now owns 138,384 shares of the company’s stock worth $4,680,000 after buying an additional 80,633 shares in the last quarter. 85.70% of the stock is owned by hedge funds and other institutional investors.
Shares of iTeos Therapeutics stock opened at $19.86 on Friday. The firm has a market capitalization of $697.17 million and a price-to-earnings ratio of -6.90. The firm has a 50 day moving average of $23.50. iTeos Therapeutics, Inc. has a fifty-two week low of $17.43 and a fifty-two week high of $47.61.
In related news, VP Yvonne Mcgrath sold 7,927 shares of the firm’s stock in a transaction on Tuesday, June 8th. The shares were sold at an average price of $20.00, for a total transaction of $158,540.00. Following the sale, the vice president now directly owns 7,927 shares in the company, valued at $158,540. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Bioventures 2014 L.P. Mpm sold 5,783 shares of the firm’s stock in a transaction on Wednesday, April 7th. The stock was sold at an average price of $32.55, for a total transaction of $188,236.65. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 21,756 shares of company stock worth $524,105. 3.95% of the stock is currently owned by company insiders.
Several analysts have recently weighed in on the stock. SVB Leerink dropped their price objective on shares of iTeos Therapeutics from $60.00 to $45.00 and set an “outperform” rating for the company in a report on Wednesday, May 19th. Wedbush raised their price objective on shares of iTeos Therapeutics from $46.00 to $52.00 and gave the stock an “outperform” rating in a report on Thursday, March 25th. Zacks Investment Research raised shares of iTeos Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, May 25th. Finally, HC Wainwright started coverage on shares of iTeos Therapeutics in a report on Wednesday, May 5th. They set a “buy” rating and a $37.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $44.83.
iTeos Therapeutics Profile
Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
Read More: What is a SEC Filing?
Want to see what other hedge funds are holding ITOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iTeos Therapeutics, Inc. (NASDAQ:ITOS).
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.